KR20240065092A - 자가면역 질환의 치료를 위한 피라졸로[3,4-b]피리딘 화합물 - Google Patents

자가면역 질환의 치료를 위한 피라졸로[3,4-b]피리딘 화합물 Download PDF

Info

Publication number
KR20240065092A
KR20240065092A KR1020247009335A KR20247009335A KR20240065092A KR 20240065092 A KR20240065092 A KR 20240065092A KR 1020247009335 A KR1020247009335 A KR 1020247009335A KR 20247009335 A KR20247009335 A KR 20247009335A KR 20240065092 A KR20240065092 A KR 20240065092A
Authority
KR
South Korea
Prior art keywords
methyl
piperidyl
pyridyl
compound
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247009335A
Other languages
English (en)
Korean (ko)
Inventor
동동 천
파비안 데이
신 홍
샤오칭 왕
지센 장
웨이 주
거 저우
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20240065092A publication Critical patent/KR20240065092A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020247009335A 2021-09-24 2022-09-22 자가면역 질환의 치료를 위한 피라졸로[3,4-b]피리딘 화합물 Pending KR20240065092A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021120406 2021-09-24
CNPCT/CN2021/120406 2021-09-24
CN2022089033 2022-04-25
CNPCT/CN2022/089033 2022-04-25
PCT/EP2022/076306 WO2023046806A1 (en) 2021-09-24 2022-09-22 Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
KR20240065092A true KR20240065092A (ko) 2024-05-14

Family

ID=83688579

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247009335A Pending KR20240065092A (ko) 2021-09-24 2022-09-22 자가면역 질환의 치료를 위한 피라졸로[3,4-b]피리딘 화합물

Country Status (16)

Country Link
US (1) US20240360126A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405051B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534567A (cg-RX-API-DMAC10.html)
KR (1) KR20240065092A (cg-RX-API-DMAC10.html)
CN (1) CN118076604A (cg-RX-API-DMAC10.html)
AR (1) AR127126A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022351495A1 (cg-RX-API-DMAC10.html)
CA (1) CA3228485A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000791A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024003401A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240134A (cg-RX-API-DMAC10.html)
IL (1) IL310443A (cg-RX-API-DMAC10.html)
MX (1) MX2024003444A (cg-RX-API-DMAC10.html)
PE (2) PE20250401A1 (cg-RX-API-DMAC10.html)
TW (1) TW202328129A (cg-RX-API-DMAC10.html)
WO (1) WO2023046806A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026515029A (ja) * 2023-04-28 2026-05-13 成都思倍博医▲薬▼科技有限公司 オキソピリド脂肪族環又は脂肪族複素環構造を含む化合物及びその医学的使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643967B2 (en) * 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
JP2021507889A (ja) * 2017-12-22 2021-02-25 ノバルティス アーゲー ピラゾロピペリジン誘導体の新規な使用
WO2019220390A1 (en) 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
CN112752755A (zh) * 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物
JP2023533807A (ja) * 2020-07-14 2023-08-04 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物

Also Published As

Publication number Publication date
EP4405051A1 (en) 2024-07-31
TW202328129A (zh) 2023-07-16
CL2024000791A1 (es) 2024-09-06
AU2022351495A1 (en) 2024-02-01
PE20240815A1 (es) 2024-04-18
CN118076604A (zh) 2024-05-24
CO2024003401A2 (es) 2024-04-29
JP2024534567A (ja) 2024-09-20
AR127126A1 (es) 2023-12-20
MX2024003444A (es) 2024-04-03
EP4405051B1 (en) 2026-07-15
PE20250401A1 (es) 2025-02-11
US20240360126A1 (en) 2024-10-31
WO2023046806A1 (en) 2023-03-30
CR20240134A (es) 2024-05-07
CA3228485A1 (en) 2023-03-30
IL310443A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
KR102698608B1 (ko) 단백질 티로신 포스파타제 억제제
JP6639607B2 (ja) 選択的に置換されたキノリン化合物
EP3802539B1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
CA2874445A1 (en) Tetrahydropyrazolopyrimidine compounds
EP3807271A1 (en) Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
EP3369734A1 (en) Kinase inhibitor, and preparing method and pharmaceutical use thereof
TW202024065A (zh) 用於治療自體免疫疾病之雜環基化合物
KR20210149163A (ko) 자가면역 질환의 치료를 위한 헥사하이드로-1H-피라지노[1,2-a]피라진 화합물
KR20230123919A (ko) Cdk 억제제 및 약제로서의 이의 용도
TW202212331A (zh) 作為egfr抑製劑之吲哚啉化合物及衍生物
US20240317735A1 (en) Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease
US20240360126A1 (en) Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease
CA3258412A1 (en) HETEROBORCTIONAL BCL6 DEGRADING AGENTS 1,8-NAPHTHYRIDIN-2-ONE
CN115835911A (zh) 用于治疗自身免疫性疾病的咪唑并[1,2-a]吡啶化合物
EA052162B1 (ru) СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
HK40107666A (en) Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease
HK40055574B (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
HK40086358A (en) Imidazo[1,2-a]pyridine compounds for the treatment of autoimmune disease
HK40048961A (en) 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application